DZ1683A1 - Composition synergique d'une substance a effet inhibiteur de la sécrétion d'acide gastrique et d'un antibiotique dégradables en milieu acide. - Google Patents

Composition synergique d'une substance a effet inhibiteur de la sécrétion d'acide gastrique et d'un antibiotique dégradables en milieu acide.

Info

Publication number
DZ1683A1
DZ1683A1 DZ930044A DZ930044A DZ1683A1 DZ 1683 A1 DZ1683 A1 DZ 1683A1 DZ 930044 A DZ930044 A DZ 930044A DZ 930044 A DZ930044 A DZ 930044A DZ 1683 A1 DZ1683 A1 DZ 1683A1
Authority
DZ
Algeria
Prior art keywords
acid
secretion
substance
inhibitory effect
synergistic composition
Prior art date
Application number
DZ930044A
Other languages
English (en)
French (fr)
Inventor
Arne Torsten Eek
Sven Erik Sjostrand
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26661401&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DZ1683(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from SE9201297A external-priority patent/SE9201297D0/xx
Priority claimed from SE9300029A external-priority patent/SE9300029D0/xx
Application filed by Astra Ab filed Critical Astra Ab
Application granted granted Critical
Publication of DZ1683A1 publication Critical patent/DZ1683A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/04—Surgical instruments, devices or methods for suturing wounds; Holders or packages for needles or suture materials
    • A61B17/0469—Suturing instruments for use in minimally invasive surgery, e.g. endoscopic surgery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/04—Surgical instruments, devices or methods for suturing wounds; Holders or packages for needles or suture materials
    • A61B17/06—Needles ; Sutures; Needle-suture combinations; Holders or packages for needles or suture materials
    • A61B17/06066—Needles, e.g. needle tip configurations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/34—Trocars; Puncturing needles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/30—Joints
    • A61F2002/30001—Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
    • A61F2002/30003—Material related properties of the prosthesis or of a coating on the prosthesis
    • A61F2002/3006—Properties of materials and coating materials
    • A61F2002/30092—Properties of materials and coating materials using shape memory or superelastic materials, e.g. nitinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2210/0014—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof using shape memory or superelastic materials, e.g. nitinol
    • A61F2210/0023—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof using shape memory or superelastic materials, e.g. nitinol operated at different temperatures whilst inside or touching the human body, heated or cooled by external energy source or cold supply
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2210/0014—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof using shape memory or superelastic materials, e.g. nitinol
    • A61F2210/0023—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof using shape memory or superelastic materials, e.g. nitinol operated at different temperatures whilst inside or touching the human body, heated or cooled by external energy source or cold supply
    • A61F2210/0047—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof using shape memory or superelastic materials, e.g. nitinol operated at different temperatures whilst inside or touching the human body, heated or cooled by external energy source or cold supply heated by light

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Surgery (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medical Informatics (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DZ930044A 1992-04-24 1993-04-07 Composition synergique d'une substance a effet inhibiteur de la sécrétion d'acide gastrique et d'un antibiotique dégradables en milieu acide. DZ1683A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9201297A SE9201297D0 (sv) 1992-04-24 1992-04-24 Synergistic combination
SE9300029A SE9300029D0 (sv) 1993-01-08 1993-01-08 Synergistic combination ii

Publications (1)

Publication Number Publication Date
DZ1683A1 true DZ1683A1 (fr) 2002-02-17

Family

ID=26661401

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ930044A DZ1683A1 (fr) 1992-04-24 1993-04-07 Composition synergique d'une substance a effet inhibiteur de la sécrétion d'acide gastrique et d'un antibiotique dégradables en milieu acide.

Country Status (38)

Country Link
US (3) US5599794A (en, 2012)
EP (2) EP0956857A3 (en, 2012)
JP (1) JPH07505901A (en, 2012)
KR (1) KR100340165B1 (en, 2012)
CN (1) CN1041798C (en, 2012)
AP (1) AP466A (en, 2012)
AT (1) ATE194286T1 (en, 2012)
AU (1) AU669903B2 (en, 2012)
CA (1) CA2133762C (en, 2012)
CZ (1) CZ291201B6 (en, 2012)
DE (2) DE637241T1 (en, 2012)
DK (1) DK0637241T3 (en, 2012)
DZ (1) DZ1683A1 (en, 2012)
EE (1) EE03149B1 (en, 2012)
ES (1) ES2100135T3 (en, 2012)
FI (1) FI944953A7 (en, 2012)
GR (2) GR970300011T1 (en, 2012)
HR (1) HRP930755B1 (en, 2012)
HU (1) HUT71225A (en, 2012)
IL (1) IL105155A (en, 2012)
IS (1) IS3990A (en, 2012)
LV (1) LV12625B (en, 2012)
MA (1) MA22878A1 (en, 2012)
MY (1) MY121189A (en, 2012)
NO (1) NO314288B1 (en, 2012)
NZ (1) NZ252759A (en, 2012)
PL (1) PL173485B1 (en, 2012)
PT (1) PT637241E (en, 2012)
RO (1) RO115780B1 (en, 2012)
RU (1) RU2143899C1 (en, 2012)
SG (1) SG52485A1 (en, 2012)
SI (1) SI9300219B (en, 2012)
SK (1) SK282420B6 (en, 2012)
TN (1) TNSN93040A1 (en, 2012)
TW (1) TW276996B (en, 2012)
UA (1) UA43830C2 (en, 2012)
WO (1) WO1993021920A1 (en, 2012)
YU (1) YU49091B (en, 2012)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW420610B (en) * 1994-04-07 2001-02-01 Pfizer A pharmaceutical composition for treating a H. pylori infection or gastric or duodenal ulcers
SE9500422D0 (sv) * 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
US6132768A (en) * 1995-07-05 2000-10-17 Byk Gulden Lomberg Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for reversible proton pump inhibitors
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6645988B2 (en) * 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
CN1061232C (zh) * 1996-04-12 2001-01-31 马理国 一种治疗胃炎、溃疡的药物组合物
SI9700186B (sl) 1997-07-14 2006-10-31 Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. Nova farmacevtska oblika z nadzorovanim sproscanjem zdravilnih ucinkovin
US6303644B1 (en) * 1997-07-25 2001-10-16 Byk Gulden Lomberg Chemische Fabrik Gmbh Proton pump inhibitor in therapeutic combination with antibacterial substances
US6174548B1 (en) 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6096340A (en) * 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6733778B1 (en) * 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6117868A (en) * 1998-09-16 2000-09-12 Ed. Geistlich Sohne Ag Fur Chemische Industrie Treatment of gastrointestinal ulcers or gastritis caused by microbial infection
US6852739B1 (en) 1999-02-26 2005-02-08 Nitromed Inc. Methods using proton pump inhibitors and nitric oxide donors
CA2362930C (en) * 1999-02-26 2010-10-05 Nitromed, Inc. Nitrosated and nitrosylated proton pump inhibitors, compositions and methods of use
US6245913B1 (en) 1999-06-30 2001-06-12 Wockhardt Europe Limited Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole
US6326384B1 (en) 1999-08-26 2001-12-04 Robert R. Whittle Dry blend pharmaceutical unit dosage form
US6312712B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Method of improving bioavailability
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6262086B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Pharmaceutical unit dosage form
US6262085B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6312723B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Pharmaceutical unit dosage form
US6316020B1 (en) * 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
US6780880B1 (en) 1999-08-26 2004-08-24 Robert R. Whittle FT-Raman spectroscopic measurement
US6268385B1 (en) 1999-08-26 2001-07-31 Robert R. Whittle Dry blend pharmaceutical formulations
US7365047B1 (en) * 1999-09-28 2008-04-29 The Regents Of The University Of California Use of pentagastrin to inhibit gastric acid secretion or as a diuretic
US20020004502A1 (en) * 2000-01-05 2002-01-10 Redmond H. Paul Treatment of inflammatory bowel disease
US6787342B2 (en) 2000-02-16 2004-09-07 Merial Limited Paste formulations
WO2001064224A1 (en) * 2000-02-29 2001-09-07 Teva Pharmaceutical Industries Ltd. Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same
AU3762801A (en) * 2000-03-09 2001-09-17 Andrew Ilchyshyn Treatment of inflammatory dermatoses comprising erythromycin or clarythromycin metronidazole and a gastrointestinal hydrogen pump inhibitor
EP1133987A1 (en) * 2000-03-09 2001-09-19 Ian Whitcroft Treatment of inflammatory dermatoses with combinations of erythromycin or clarythromycin, metronidazole and a hydrogen pump inhibitor
IL151888A0 (en) * 2000-03-28 2003-04-10 Biochemie Gmbh Granulated particles with masked taste
SE0002476D0 (sv) 2000-06-30 2000-06-30 Astrazeneca Ab New compounds
US6544556B1 (en) 2000-09-11 2003-04-08 Andrx Corporation Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor
WO2002026210A2 (en) * 2000-09-29 2002-04-04 Geneva Pharmaceuticals Inc. Proton pump inhibitor formulation
SE0103695D0 (sv) 2001-11-07 2001-11-07 Thomas Boren A novel non-antibiotic strategy against OGIP infections based on a cereal product
AU2002365936A1 (en) * 2001-11-16 2003-09-02 Eisai Co. Ltd Compositions and methods to treat gastrointestinal disorders
US20040006111A1 (en) * 2002-01-25 2004-01-08 Kenneth Widder Transmucosal delivery of proton pump inhibitors
US20030228363A1 (en) * 2002-06-07 2003-12-11 Patel Mahendra R. Stabilized pharmaceutical compositons containing benzimidazole compounds
EP1534278A4 (en) * 2002-08-01 2006-09-06 Nitromed Inc NITROSED PROTONATE PUMP INHIBITORS, COMPOSITIONS AND USE METHOD
US7678816B2 (en) * 2003-02-05 2010-03-16 Teva Pharmaceutical Industries Ltd. Method of stabilizing lansoprazole
WO2004073654A2 (en) * 2003-02-20 2004-09-02 Santarus, Inc. A novel formulation, omeprazole antacid complex-immediate release for rapid and sustained supression of gastric acid
US20040185092A1 (en) * 2003-03-18 2004-09-23 Yih Ming Hsiao Pharmaceutical preparations of omeprazole and/or clarithromycin for oral use
CA2531566C (en) * 2003-07-18 2013-05-07 Santarus, Inc. Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders
US8993599B2 (en) * 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
JP2006528181A (ja) * 2003-07-18 2006-12-14 サンタラス インコーポレイティッド 酸分泌を阻害するために有用な薬学的製剤ならびにそれらを作製および使用する方法
US8906940B2 (en) * 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en) * 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20060194748A1 (en) * 2005-02-28 2006-08-31 National University Corporation Nagoya University Methods for treating disorders induced by H. pylori infections and pharmaceutical compositions for the same
WO2007070164A1 (en) * 2005-10-19 2007-06-21 The Curators Of The University Of Missouri Pharmaceutical composition comprising a proton pump inhibitor, a buffering agent and an anti-h. pylori active substance and methods of using same
US20070141151A1 (en) * 2005-12-20 2007-06-21 Silver David I Lansoprazole orally disintegrating tablets
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
CA2665226C (en) 2006-10-05 2014-05-13 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
AU2007317561A1 (en) 2006-10-27 2008-05-15 The Curators Of The University Of Missouri Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
US10869690B2 (en) * 2017-06-29 2020-12-22 Ethicon Llc Trocar obturator with transverse needle ports
WO2024075017A1 (en) 2022-10-04 2024-04-11 Zabirnyk Arsenii Inhibition of aortic valve calcification

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85472A (en) * 1987-03-09 1991-06-30 Procter & Gamble Pharmaceutical compositions for treating gastrointestinal disorders
JP2694361B2 (ja) * 1989-02-09 1997-12-24 アストラ アクチエボラグ 抗菌剤
ES2066120T3 (es) * 1989-02-10 1995-03-01 Takeda Chemical Industries Ltd Uso de derivados de bencimidazol como agentes antibacterianos.
GB9018603D0 (en) * 1990-08-24 1990-10-10 Smith Kline French Lab Compositions
DK0548103T3 (da) * 1990-09-14 2002-04-02 Byk Gulden Lomberg Chem Fab Anvendelse af pyridylmethylsulfinyl-1H-benzimidazolderivater til behandling af sygdomme, der er fremkaldt af Helicobacter-bakterier

Also Published As

Publication number Publication date
WO1993021920A1 (en) 1993-11-11
CZ259394A3 (en) 1995-08-16
GR970300011T1 (en) 1997-05-31
TW276996B (en, 2012) 1996-06-01
MA22878A1 (fr) 1993-12-31
US5629305A (en) 1997-05-13
EP0637241B1 (en) 2000-07-05
RU2143899C1 (ru) 2000-01-10
PT637241E (pt) 2000-10-31
PL173485B1 (pl) 1998-03-31
CZ291201B6 (cs) 2003-01-15
YU49091B (sh) 2003-12-31
DE69328967D1 (de) 2000-08-10
LV12625B (en) 2001-07-20
ES2100135T3 (es) 2000-11-16
NO314288B1 (no) 2003-03-03
CA2133762C (en) 2000-08-01
CN1081614A (zh) 1994-02-09
SI9300219A (sl) 1993-12-31
AP466A (en) 1996-03-05
LV12625A (en) 2001-03-20
SK127594A3 (en) 1995-04-12
DE637241T1 (de) 1997-09-11
ES2100135T1 (es) 1997-06-16
IS3990A (is) 1993-10-25
CN1041798C (zh) 1999-01-27
DK0637241T3 (da) 2000-09-11
UA43830C2 (uk) 2002-01-15
DE69328967T2 (de) 2000-12-07
RO115780B1 (ro) 2000-06-30
GR3034470T3 (en) 2000-12-29
NZ252759A (en) 1996-12-20
HU9403069D0 (en) 1994-12-28
EP0956857A3 (en) 2003-11-26
AU669903B2 (en) 1996-06-27
US5633244A (en) 1997-05-27
EE03149B1 (et) 1999-02-15
IL105155A (en) 1999-05-09
NO944010D0 (no) 1994-10-21
EP0956857A2 (en) 1999-11-17
US5599794A (en) 1997-02-04
TNSN93040A1 (fr) 1994-03-17
ATE194286T1 (de) 2000-07-15
AU4273793A (en) 1993-11-29
JPH07505901A (ja) 1995-06-29
MY121189A (en) 2006-01-28
FI944953A0 (fi) 1994-10-21
EP0637241A1 (en) 1995-02-08
KR100340165B1 (ko) 2002-10-04
HK1008296A1 (en) 1999-05-07
SG52485A1 (en) 1998-09-28
YU27593A (sh) 1996-10-09
SI9300219B (en) 2001-12-31
CA2133762A1 (en) 1993-11-11
SK282420B6 (sk) 2002-01-07
FI944953L (fi) 1994-10-21
HRP930755A2 (en) 1994-10-31
AP9300518A0 (en) 1993-04-30
IL105155A0 (en) 1993-07-08
NO944010L (no) 1994-10-21
FI944953A7 (fi) 1994-10-21
HUT71225A (en) 1995-11-28
HRP930755B1 (en) 2001-04-30

Similar Documents

Publication Publication Date Title
DZ1683A1 (fr) Composition synergique d'une substance a effet inhibiteur de la sécrétion d'acide gastrique et d'un antibiotique dégradables en milieu acide.
BR9205818A (pt) Composições azeotrópicas de 1,1,2,2-tetrafluororetano e semelhantes.
FI941747L (fi) Koostumuksia ja niiden käyttöjä
PH30794A (en) Inhibition of phosphatidylinositol 3-kinase with worthmannin and analogs thereof.
BR1100824A (pt) Composto e composição farmacêutica
ITMI951021A0 (it) Composizioni farmaceutiche e/o dietetiche ad attivita' antiossidante
DE3887233D1 (de) Hemmung von Mineralabsetzung mit Hilfe von polyanionischen/hydrophobischen Peptiden und deren Derivaten.
KR960008915B1 (en) Water and oil repelling film and method of manufacturing the same
AP9200426A0 (en) Substance or composition and uses thereof
GB2271059B (en) Pharmaceutical compositions comprising aconitane derivatives and tetrahydroprotoberberine derivatives.
BR9200058A (pt) Composto e composicao farmaceutica
FI953411L (fi) Polyhydroksialkanoaatteja ja kalvon muodostus niistä
NO954767D0 (no) 4-amino-17 delser som C17-20-lyase- og 5
BR9205843A (pt) Composição inseticida e unidades inseticidas
NO931011D0 (no) 7-okso-7h-pyrido(1,2,3-de)(1,4)benzoksacin-6-karbonsyrer og -estere
ATE122206T1 (de) Verminderung und inhibition des gehalts von äthylenthioharnstoff in alkylenbisdithiocarbamaten.
ZA897505B (en) Stable oxapenem-3-carboxylic acids and their use as beta-lactamase inhibitors
GB2259703B (en) N-(N'-long chain acyl-ß-alanyl)-ß-alanine or its salt and detergent composition containing the same
FR2677250B1 (fr) Compositions pharmaceutiques contenant de l'adenosine-5-triphosphate disodique.
FR2684299B1 (fr) Compositions pharmaceutiques contenant de l'adenosine-5-triphosphate disodique et de l'amiloride.
FR2684682B1 (fr) Composition pour la protection et la preservation de surfaces vis-a-vis des graffitis, et ses applications.
RU2001649C1 (ru) Тренажер
FR2687362B1 (fr) Bateau notamment motorise.
LV10475A (lv) Panemiens fermentu inicietas 1,2-dioksetanu hemoluminiscenses pastiprinasanai un ta pielietojums
ZA928419B (en) Pharmaceutical substances or compositions and their use